Mear ynformaasje ― Frysk

Urticarial vasculitis is in seldsume tastân markearre troch langduorjende of weromkommende ôfleverings fan hives. Wylst har hûdsymptomen lykje kinne op chronike hives, binne se unyk om't de hives op syn minst 24 oeren bliuwe en donkere plakken kinne feroarsaakje nei it ferdwinen. Hoewol faaks fan ûnbekende oarsaak, kin it soms wurde trigger troch bepaalde medisinen, ynfeksjes, autoimmune sykten, bloedsteurnissen of kankers. Guon stúdzjes hawwe it sels keppele oan COVID-19 en H1N1 gryp. It kin ek ynfloed op oare dielen fan it lichem lykas spieren, nieren, longen, mage, en eagen. Wylst in bepaalde soarte fan tissue-ûndersyk de diagnoaze befestigje kin, is it net altyd nedich. Behanneling begjint typysk mei antibiotika, dapsone, colchicine, of hydroxychloroquine foar mildere gefallen. Foar slimmer gefallen kinne medisinen nedich wêze dy't it ymmúnsysteem ûnderdrukke, lykas methotrexate of kortikosteroïden. Koartlyn hawwe biologyske terapyen (rituximab, omalizumab, interleukin-1 inhibitors) belofte toand foar drege gefallen.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

In 35-jierrige man kaam binnen mei in 15-dagen skiednis fan helder read, pynlike útslach op beide dijen en skonken, tegearre mei mienskiplike pine. Hy hie in wike urinewegynfeksje foardat de útslach ferskynde. Syn hûd toande ferskate sêfte, ringfoarmige, foar in part blanchable, reade plakken oan beide kanten fan syn dijen en skonken. Hy krige mûnlinge prednisolon (40mg / dei) foar in wike tegearre mei in net-sufige antystamine (fexofenadine) . Binnen in wike ferdwûn alle útslach hielendal. D'r wiene gjin útslach mear yn 'e folgjende 6 moannen fan reguliere kontrôles.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.